Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Conditions:   Breast Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Ref ractory Nodal Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Drug: Belinostat;   Drug: Carfilzomib;   Biological: Daratumumab;   Drug: Fludeoxyglucose F-18;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Obinutuzumab;   Biological: Pembrolizumab;   Procedure: Positro n Emission Tomography;   Biological: Rituximab;   Drug: Romidepsin;   Other: Saline;   Biological: Trastuzumab Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials